70 related articles for article (PubMed ID: 30213587)
1. Incidence of Progression of Persistent Nondysplastic Barrett's Esophagus to Malignancy.
Peters Y; Honing J; Kievit W; Kestens C; Pestman W; Nagtegaal ID; van der Post RS; Siersema PD
Clin Gastroenterol Hepatol; 2019 Apr; 17(5):869-877.e5. PubMed ID: 30213587
[TBL] [Abstract][Full Text] [Related]
2. A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus.
Critchley-Thorne RJ; Davison JM; Prichard JW; Reese LM; Zhang Y; Repa K; Li J; Diehl DL; Jhala NC; Ginsberg GG; DeMarshall M; Foxwell T; Jobe BA; Zaidi AH; Duits LC; Bergman JJ; Rustgi A; Falk GW
Cancer Epidemiol Biomarkers Prev; 2017 Feb; 26(2):240-248. PubMed ID: 27729357
[TBL] [Abstract][Full Text] [Related]
3. Use of Appropriate Surveillance for Patients With Nondysplastic Barrett's Esophagus.
Tavakkoli A; Appelman HD; Beer DG; Madiyal C; Khodadost M; Nofz K; Metko V; Elta G; Wang T; Rubenstein JH
Clin Gastroenterol Hepatol; 2018 Jun; 16(6):862-869.e3. PubMed ID: 29432922
[TBL] [Abstract][Full Text] [Related]
4. A biomarker panel predicts progression of Barrett's esophagus to esophageal adenocarcinoma.
Duits LC; Lao-Sirieix P; Wolf WA; O'Donovan M; Galeano-Dalmau N; Meijer SL; Offerhaus GJA; Redman J; Crawte J; Zeki S; Pouw RE; Chak A; Shaheen NJ; Bergman JJGHM; Fitzgerald RC
Dis Esophagus; 2019 Jan; 32(1):. PubMed ID: 30496496
[TBL] [Abstract][Full Text] [Related]
5. Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett's Esophagus, and Barrett's Esophagus-Related Neoplasia in the United States.
Sharma P; Falk GW; Bhor M; Ozbay AB; Latremouille-Viau D; Guerin A; Shi S; Elvekrog MM; Limburg P
J Health Econ Outcomes Res; 2023; 10(1):51-58. PubMed ID: 36883055
[No Abstract] [Full Text] [Related]
6. Significance of Crypt Atypia in Barrett's Esophagus: A Clinical, Molecular, and Outcome Study.
Wang HH; Patil DT; Paulson TG; Grady WM; Odze RD
Clin Gastroenterol Hepatol; 2024 Apr; 22(4):741-748.e2. PubMed ID: 37879518
[TBL] [Abstract][Full Text] [Related]
7. Neoplasia Detection Rate in Barrett's Esophagus and Its Impact on Missed Dysplasia: Results from a Large Population-Based Database.
Dhaliwal L; Codipilly DC; Gandhi P; Johnson ML; Lansing R; Wang KK; Leggett CL; Katzka DA; Iyer PG
Clin Gastroenterol Hepatol; 2021 May; 19(5):922-929.e1. PubMed ID: 32707339
[TBL] [Abstract][Full Text] [Related]
8. A Tissue Systems Pathology Test Outperforms the Standard-of-Care Variables in Predicting Progression in Patients With Barrett's Esophagus.
Davison JM; Goldblum JR; Duits LC; Khoshiwal AM; Bergman JJ; Falk GW; Diehl DL; Khara HS; Smolko C; Arora M; Siegel JJ; Critchley-Thorne RJ; Thota PN
Clin Transl Gastroenterol; 2023 Nov; 14(11):e00631. PubMed ID: 37622544
[TBL] [Abstract][Full Text] [Related]
9. Optimizing Management of Patients With Barrett's Esophagus and Low-Grade or No Dysplasia Based on Comparative Modeling.
Omidvari AH; Ali A; Hazelton WD; Kroep S; Lee M; Naber SK; Lauren BN; Ostvar S; Richmond E; Kong CY; Rubenstein JH; Lansdorp-Vogelaar I; Luebeck G; Hur C; Inadomi J
Clin Gastroenterol Hepatol; 2020 Aug; 18(9):1961-1969. PubMed ID: 31816445
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and Predictors of Missed Dysplasia on Index Barrett's Esophagus Diagnosing Endoscopy in a Veteran Population.
Nguyen TH; Thrift AP; George R; Rosen DG; El-Serag HB; Ketwaroo GA
Clin Gastroenterol Hepatol; 2022 Apr; 20(4):e876-e889. PubMed ID: 33839273
[TBL] [Abstract][Full Text] [Related]
11. Incidence and Prediction of Unrelated Mortality After Successful Endoscopic Eradication Therapy for Barrett's Neoplasia.
van Munster SN; Verheij EPD; Ozdemir Ö; Toes-Zoutendijk E; Lansdorp-Vogelaar I; Nieuwenhuis EA; Cotton CC; Weusten BLAM; Alvarez Herrero L; Alkhalaf A; Schenk BE; Schoon EJ; Curvers WL; Koch AD; de Jonge PF; Tang TJ; Nagengast WB; Westerhof J; Houben MHMG; Shaheen NJ; Bergman JJGHM; Pouw RE
Gastroenterology; 2024 Jun; 166(6):1058-1068. PubMed ID: 38447738
[TBL] [Abstract][Full Text] [Related]
12. Population Based Time Trends in the Epidemiology and Mortality of Gastroesophageal Junction and Esophageal Adenocarcinoma.
Agarwal S; Bell MG; Dhaliwal L; Codipilly DC; Dierkhising RA; Lansing R; Gibbons EE; Leggett CL; Kisiel JB; Iyer PG
Dig Dis Sci; 2024 Jan; 69(1):246-253. PubMed ID: 37914889
[TBL] [Abstract][Full Text] [Related]
13. The Salivary Microbiome and Predicted Metabolite Production Are Associated with Barrett's Esophagus and High-Grade Dysplasia or Adenocarcinoma.
Solfisburg QS; Baldini F; Baldwin-Hunter B; Austin GI; Lee HH; Park H; Freedberg DE; Lightdale CJ; Korem T; Abrams JA
Cancer Epidemiol Biomarkers Prev; 2024 Mar; 33(3):371-380. PubMed ID: 38117184
[TBL] [Abstract][Full Text] [Related]
14. Multicenter, Prospective Trial of Nonendoscopic Biomarker-Driven Detection of Barrett's Esophagus and Esophageal Adenocarcinoma.
Moinova HR; Verma S; Dumot J; Faulx A; Iyer PG; Canto MI; Wang JS; Shaheen NJ; Thota PN; Aklog L; Willis JE; Markowitz SD; Chak A
Am J Gastroenterol; 2024 May; ():. PubMed ID: 38686933
[TBL] [Abstract][Full Text] [Related]
15. Dating the rise of esophageal adenocarcinoma: analysis of Connecticut Tumor Registry data, 1940-2007.
Abrams JA; Sharaiha RZ; Gonsalves L; Lightdale CJ; Neugut AI
Cancer Epidemiol Biomarkers Prev; 2011 Jan; 20(1):183-6. PubMed ID: 21127287
[TBL] [Abstract][Full Text] [Related]
16. Exploring the recent trend in esophageal adenocarcinoma incidence and mortality using comparative simulation modeling.
Kong CY; Kroep S; Curtius K; Hazelton WD; Jeon J; Meza R; Heberle CR; Miller MC; Choi SE; Lansdorp-Vogelaar I; van Ballegooijen M; Feuer EJ; Inadomi JM; Hur C; Luebeck EG
Cancer Epidemiol Biomarkers Prev; 2014 Jun; 23(6):997-1006. PubMed ID: 24692500
[TBL] [Abstract][Full Text] [Related]
17. Some observations on Barrett esophagus and associated dysplasia.
Montgomery E; Arnold CA; Lam-Himlin D; Salimian K; Waters K
Ann Diagn Pathol; 2018 Dec; 37():75-82. PubMed ID: 30312881
[TBL] [Abstract][Full Text] [Related]
18. Oesophageal cell collection device and biomarker testing to identify high-risk Barrett's patients requiring endoscopic investigation.
Chien S; Glen P; Penman I; Cruickshank N; Bryce G; Crumley A; Phull P; Miller M; Fletcher J; Gunjaca I; Apollos J; Robertson K; Fullarton G
Br J Surg; 2024 May; 111(5):. PubMed ID: 38736137
[TBL] [Abstract][Full Text] [Related]
19. Professionals' views on the justification for esophageal adenocarcinoma screening: A systematic literature search and qualitative analysis.
Sijben J; Peters Y; Rainey L; Gashi M; Broeders MJM; Siersema PD
Prev Med Rep; 2023 Aug; 34():102264. PubMed ID: 37273526
[TBL] [Abstract][Full Text] [Related]
20. Categorizing Risks within Barrett's Esophagus To Guide Surveillance and Interception; Suggesting a New Framework.
Honing J; Fitzgerald RC
Cancer Prev Res (Phila); 2023 Jun; 16(6):313-320. PubMed ID: 37259801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
